Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ingenol Mebutate

FDA-approved product (gel, topical), marketed as Ingenol Mebutate, Picato.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ingenol Mebutate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Actinic keratosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other chemotherapeutics
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D06BX02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ingenol Mebutate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ingenol Mebutate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ

    NCT00329121 · start 2006-05

    Registered record
    Registry ID
    NCT00329121
    Conditions
    Carcinoma, Squamous Cell
    Interventions
    PEP005
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-05
    Completion
    2006-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Squamous Cell
    InterventionPEP005
    PhasePhase 2
    Registry statusCompleted

  • Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

    NCT00239135 · start 2005-09

    Registered record
    Registry ID
    NCT00239135
    Conditions
    Keratosis
    Interventions
    PEP005
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    2005-12
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratosis
    InterventionPEP005
    PhasePhase 2
    Registry statusCompleted

  • Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

    NCT00107965 · start 2005-03

    Registered record
    Registry ID
    NCT00107965
    Conditions
    Actinic Keratosis
    Interventions
    PEP005; PEP005; PEP005; PEP005; PEP005; PEP005; PEP005; PEP005
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-03
    Completion
    2005-09
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionPEP005; PEP005; PEP005; PEP005 +4 more
    PhasePhase 2
    Registry statusCompleted

  • Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma

    NCT00108121 · start 2005-03

    Registered record
    Registry ID
    NCT00108121
    Conditions
    Basal Cell Carcinoma
    Interventions
    PEP005
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-03
    Completion
    2006-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma
    InterventionPEP005
    PhasePhase 2
    Registry statusCompleted

  • Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma

    NCT00108134 · start 2005-03

    Registered record
    Registry ID
    NCT00108134
    Conditions
    Basal Cell Carcinoma
    Interventions
    PEP005
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-03
    Completion
    2006-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma
    InterventionPEP005
    PhasePhase 2
    Registry statusCompleted